Targeted expression of genes coding for proteins specific to astrocytes, oligodendrocytes and myelin 10 was performed in frontal cortex area 8 of Creutzfeldt-Jakob disease methionine/methionine and valine/valine (CJD MM1 and VV2, respectively) compared with controls. GFAP (glial fibrillary acidic protein) mRNA was up-regulated whereas SLC1A2 (solute carrier family 1 member 2, coding for glutamate transporter 1: GLT1), AQ4 (aquaporin 4), MPC1 (mitochondrial pyruvate carrier 1) and UCP5 (mitochondrial uncoupled protein 5) mRNAs were significantly down-regulated in CJD MM1 15 and CJD VV2, and GJA1 (connexin 43) in CJD VV2. OLIG1 and OLIG2 (oligodendocyte transcription factor 1 and 2, respectively), SOX10 (SRY-Box10) and oligodendroglial precursor cell (OPC) marker NG2 (neuronal/glial antigen) 2 were preserved, but GALC (coding for galactosylceramidase), SLC2A1 (solute carrier family 2 member 1: glucose transporter member 1: GLUT1) and MCT1 (monocarboxylic acid transporter 1) mRNA expression levels were significantly reduced in CJD MM1 and CJD VV2.
Introduction
Prion diseases are a group of transmissible encephalo-30 pathies linked to the prion protein (PrP C ) which is converted into an abnormally conformed proteinase K-resistant protein named prion (PrP SC ). The human prion diseases are sporadic, iatrogenic and genetic Creutzfeld-Jakob disease (sCJD, iCJD and gCJD, 35 respectively), Gerstmann-Straüsler-Scheinker disease (GSS) disease, and fatal familial insomnia (FFI). gCJD, GSS and FFI are due to mutations in prion protein gene (PRNP) [1] [2] [3] [4] [5] [6] [7] . The main prionopathies in animals are scrapie (typical and atypical) in sheep and goats; 40 chronic wasting disease in deer, elk, moose and reindeer; and bovine spongiform encephalopathy (BSE) in cattle [8] .Variant CJD (vCJD) is considered a form of BSE transmitted to humans [9] . CJD is not homogeneous; different subtypes are distinguished in sCJD 45 depending on the prion type (I and 2) and the composition of codon 129 in PRNP (methionine/methionine:
MM, valine/valine: VV, and methionine/valine: MV), each one with singular clinical phenotypes [10, 11] . The most frequent subtypes are sCJD MM1 and sCJD VV2.
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Common neuropathological lesions in CJD are neuron loss, spongiform change and deposition of PrP SC . Additional characteristics of sCJD MM1 are microvacuolar spongiform change in the frontal and occipital cortices, and molecular layer of the cerebellum, and 55 synaptic-like PrP SC deposition. Particular features of sCJD VV2 are microvacuolar or confluent spongiform change, major involvement of the cerebellum, and synaptic, perineuronal and plaque-like PrP SC deposits [4] [5] [6] [7] . Reactive astrocytosis and microgliosis, accompa-60 nied by a robust molecular inflammatory response, are important accompanying features [12] [13] [14] [15] .
Besides their contribution to astrocytic gliosis and inflammation, little is known about the defects of astrocytes in CJD. In addition to neuronal bodies, dendrites, and microglia [16] . Aquaporin 1 and 4 immunoreactivity is increased [17, 18] , thus suggesting adaptation to water transport. Moreover, recent studies have shown that human astrocytes have the capacity to take up and 70 degrade normal and protease-resistant prion protein [19] and that they can transfer PrP SC to neurons via nanotubules [20] thereby contributing to prion disease progression.
Regarding oligodendrocytes, less information is 75 available in CJD. Oligodendrocytes are apparently resistant to PrP SC infectivity [21] . However, axon and myelin damage occurs in prion diseases [22] , abnormal interactions between oligodendroglia and astrocytes are found in experimental CJD and scrapie [23] , and 80 engulfment of oligodendrocytes by hypertrophic astrocytes has been reported in the white matter in CJD [24] . PRP SC is also localized as arrays adjacent to myelin fibers in the cerebrum and cerebellum in CJD [25] .
Based on these data, the present study was under-85 taken to gain understanding about transcription alteration of genes encoding proteins specifically expressed in astrocytes and oligodendrocytes in frontal cortex area 8 of CJD MM1 and CJD VV2. Selected genes include those encoding structural proteins of astrocytes and 90 myelin, those involved in energy metabolism and axon maintenance, and genes of connexins of the gap junctions between oligodendrocytes and astrocytes. Protein expression of altered has been assessed by immunohistochemistry. when compared with controls (P = 0.007) and with CJD MM1 (P = 0.004) (Figure 1(a) ). ANCOVA's contrast analysis revealed significant GALC mRNA down-regulation in CJD MM1 and CJD VV2 (P = 0.001 and P = 0.000, respectively). . All data are expressed as mean ± SEM. Differences between groups are considered statistically significant at * P < 0.05, ** P < 0.01, *** P < 0.001 when comparing CJD cases with controls; and set at $ P < 0.05 and $$ P < 0.01 when comparing CJD MM1 with CJD VV2. respectively. GJB1, GJC2 and CLDN11 expression was not modified in CJD, although there was a trend to decrease in CJD MM1, when compared with controls ( Figure 1(b) ).
Results

Astrocytic markers
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Immunohistochemistry
Paraffin sections processed for immunohistochemistry showed marked increase in GFAP immunoreactivity in CJD when compared with controls, as expected. GFAPimmunoreacytive astrocytes were increased in number,
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and the amount of GFAP was increased per astrocyte with robust immunostaining of astrocyte processes ( Figure 2 ). In contrast, OLig-2 immunostaining in the cerebral cortex did not reveal major differences between CJD and controls ( Figure 2 ). Aquaporin 4
235
(AQP4) immunoreactive localized in astrocytes delineating fine and varicose network processes in control cerebral cortex. AQP4 immunoreactivity in CJD was variable from one case to another yet preserving the same morphological profile (Figure 2 ). In advanced 240 cases, AQP4 immunoreactivity was increased and blurred as reported elsewhere. GLT1 immunoreactivity in control cases was seen as delicate meshwork of fine and varicose processes around the nuclei of astrocytes. This pattern was preserved in CJD, although with 245 marked differences from one case to another; in some cases GLT1 immunoreactivity practically disappeared in areas with severe spongiform change while it was practically preserved in others; Moreover variations were also observed in different areas in the same tissue 250 section ( Figure 2 ). MPC1 was mainly localized in the cytoplasm of neurons in the cerebral cortex of control cases as a punctuate immunostaining consistent with a mitochondrial localization. MPC1 immunoreactivity was dramatically reduced in neurons in CJD but 255 increased in a few cortical glial cells (Figure 2) .
Similarly, UPC5 immunostaining mainly decorated neurons in controls. However, UPC5 immunoreactivity decreased in neurons but increased in glial cells, mainly in cells with astrocyte morphology, in CJD (Figure 2 ).
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GLUT1 was mainly found in the walls of small blood vessels consistent with endothelial localization as expected. In addition, GLUT1 immunoractivity was found as blurred patches in the cortical neuropil in control cases; these patches were markedly reduced in 265 size and intensity in CJD (Figure 2) . Finally, MCT1 was mainly localized in endothelial cells and to a lesser degree in neurons and glial cells in controls. Marked reduction in MCT1 immunoractivity was found in neurons and glial cells, but not in endothelial cells, in 270 CJD (Figure 2 ).
Discussion
The present study is focused on astrocytes and oligodendrocytes of the frontal cortex area 8 in CJD MM1 and VV2 compared to controls. In spite of the opti-275 cally-monitored separation of the cerebral cortex from the underlying white matter, contamination by subcortical U fibers cannot be ruled out in our study. This is convenient remark as astrocytes and oligodendrocytes in grey matter differ from astrocytes and oligodendro-280 cytes in white matter, and from one region to another.
Astrogliosis is one of the characteristic neuropathological lesions in cerebral cortex CJD which is here manifested by increased significant GFAP mRNA expression, as previously reported [15] . However, no 285 significant differences are seen in the expression levels of the gene coding for aldehyde dehydrogenase 1 family member L1 (ALDH1L1) used as a marker of the total astrocyte population. Aquaporin 4 protein levels, as revealed by gel electrophoresis and western blotting, 290 are markedly increased in CJD [17] . This is in contrast with the down-regulation of AQP4 mRNA in CJD MM1 and CJD VV2, here observed. Yet, AQP4 immunoreactivity is variable from one case to another: AQP4 immunorecativity is apparently decreased in 295 some cases, increased in others, and even increased and blurred in cases with severe spongiform change. We do not have an explanation for this point; enhanced translation and/or reduced degradation can account for discrepancies between mRNA and protein expression, and 300 for case-to-case and area differences in protein immunoreactivity. Expression of solute carrier family 1A2 important aspects as blood-derived glucose through GLUT1 is metabolized via glycolysis to produce piruvate and lactate which are delivered to the axons through specific solute carriers, the monocarboxylase transporters (MCTs) located in cell membranes [26, 27] .
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In glia, MCT1 is mainly expressed in developing oligodendrocytes and MCT4 in astrocytes [28, 29] . Inhibition of MCT1 in organotypic cultures of the spinal cord in glucose-deprived media is toxic to neurons; the effects on neurons are reversed with the addition of lactate 335 into the medium [29] ; moreover, reduction of MCT1 activity in vivo results in axonal damage [29] .
These changes are not accompanied by altered expression of oligodendroglial markers OLIG1, OLIG2 and SOX10 [30] ; and adult oligodendroglial precursors 340 (NG2) [31, 32] . The expression of genes encoding main myelin proteins is also preserved in frontal cortex in CJD, including myelin basic protein (MBP), proteolipid protein (PLP), 2ʹ,3ʹ-cyclic nucleotide-3ʹphosphodiesterase (CNP), myelin-associated glycoprotein (MAG), myelin oligoden-345 drocyte glycoprotein (MOG) and myelin/oligodendrocyte basic protein (MOBP) [33] [34] [35] .The expression of CLDN11, the gene encoding for claudin 11, principal component of tight junctions of myelin connections at their edges [36, 37] , is not modified in CJD. The expres-350 sion of MYRF, encoding myelin regulatory factor which triggers myelination following binding to several promoters of genes coding for myelin proteins [38] , is maintained in CJD. In contrast, the expression of the gene coding for galactocerebrosidase (GALC) is reduced in 355 CJD MM1 and VV2, thus indicating possible impairment in glycosphingolipid metabolism. To our knowledge, most studies of brain lipids in CJD were carried out many years ago and the main focus was on ganglioside alterations [39] [40] [41] [42] . Since the present studies are focused 360 on the cerebral cortex, further investigation is needed to get information about brain lipid alterations in the white matter in prion diseases.
Oligodendrocytes are connected with each other and with astrocytes through gap junctions thus forming a 365 glial syncytium in the white matter tracts [43, 44] . Gap junctions are composed of connexins (Cx); Cx32 and Cx47 are synthesized by oligodendrocytes, and Cx30 and Cx43 by astrocytes [45] . The expression of genes coding for Cx32 (GJB1) and Cx47 (GJC2), and Cx30 (GJB6) is 370 similar in CJD and in control cases, but GJA1 (encoding Cx43) mRNA expression is reduced in CJD VV2 when compared with controls and CJD MM1. Whether these changes have implications in the normal function of the glial syncitium deserves further attention.
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Interpretation of some of the present data must be taken with caution. MPC1 is expressed in brain [46] principally in neurons in controls. MPC1 immunoreactivity is reduced in neurons but increased in glial cells in CJD. Therefore, the origin of decreased MPC1 mRNA 380 expression in CJD here observed may be due to damaged neurons, whereas MPC1 protein is increased in glial cells. Similarly, UC5P in the brain is mainly expressed in neurons [47] ; reduced UCP5 mRNA expression here observed in CJD is accompanied by reduced UPC5 385 immunoreactivity in neurons, but this accompanied by increased immunoreactivity in glial cells with the morphology of astrocytes. GLUT1 is largely expressed in red blood cells and endothelial cells, including brain microvessels [48, 49] . No 390 alterations in GLUT1 immunoreactivity is found in CJD microvessels; reduction of GLUT1 mRNA correlates with decreased GLUT1 immunoreactivity in the neuropil in CJD. Finally, MCT1 is widely expressed in endothelial cells in brain [50] [51] [52] , but also in glial cells especially during 395 development [53, 54] . MCT1 immunoreactivity in the adult brain is also observed in neurons. MCT1 immunoractivity is preserved in endothelial cells in CJD when compared with controls; reduced MCT1 mRNA and protein in CJD can be ascribed to reduced expression in neurons.
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The concepts of astrocytopathy and oligodendrocytopathy, referring to molecular alterations in astrocytes and oligodendrocytes, are appropriate in neurodegenerative diseases with abnormal protein aggregates [55] [56] [57] [58] [59] [60] . This study supports the idea that molecular flaws in astrocytes 405 and oligodendrocytes, in addition to neurons, are relevant in the pathogenesis of cortical alterations in CJD. plates over dry ice and stored at −80ºC until use. Part of this material was used for gel electrophoresis and western blotting for identification of protease-resistant PrP type. CJD was diagnosed following well-established neuropathological criteria, codon 129 genotype and character-455 istics of PrP pattern on western blots [61] . None of the cases had suffered from panencephalopathic CJD [62] . Additional brain pathology consisting of neurofibrillary tangles at stages I-II of Braak and Braak, argyrophilic grain disease stage 2, mild small blood vessel disease, 460 and Lewy bodies in the brain stem in some individuals were expected with the age of the patients. Similar lesions were found in the control group and, therefore, they were not contemplated as discriminating variables. The whole series included 7 CJD MM1 (4 men and 3 465 women; age: 70.5 ± 5.5), 10 CJD VV2 (4 men and 6 women; age 66.5 ± 6.85) and 10 controls (6 men and 4 women, age 67.1 ± 7.6). A summary of cases is shown in Table 1 . Biochemical studies were carried out in the frontal cortex area 8 after our best optically-monitored dissec-470 tion of the cerebral cortex and white matter. However, inclusion of white matter subcortical U fibers cannot be ruled out in the present study.
Material and methods
Human cases
RNA purification
RNA from frozen frontal cortex area 8 was extracted fol-475 lowing the instructions of the supplier (RNeasy Mini Kit, Qiagen® GmbH, Hilden, Germany). RNA integrity and 28S/18S ratios were determined with the Agilent Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA, USA). RIN values are shown in Table 1 : control 6.76 ± 0.5; 480 CJD MM1 5.68 ± 0.8 and CJD VV2 5.84 ± 0.6). Samples were treated with DNase digestion, and RNA concentration was evaluated using a NanoDrop™ Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Rt-qPCR
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TaqMan RT-qPCR assays were performed in duplicate for each gene on cDNA samples in 384-well optical plates using an
AQ9
� ABI Prism 7900 Sequence Detection system (Applied Biosystems, Life Technologies, Waltham, MA, USA).� Probes are listed in Table II .
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For each 10μL TaqMan reaction, 4.5μL cDNA was mixed with 0.5μL 20x TaqMan Gene Expression Assays and 5μL of 2x TaqMan Universal PCR Master Mix (Applied Biosystems). Values of GUS-β were used as internal controls for normalization [63] .
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The parameters of the reactions were 50°C for 2min, 95°C for 10min, and 40 cycles of 95°C for 15sec and 60°C for 1min. Finally, capture of all TaqMan PCR data used the Sequence Detection Software (SDS version 2.2.2, Applied Biosystems). For the data analysis, 500 threshold cycle (CT) values for each sample were processed to obtain the double delta CT (ΔΔCT) values. First, delta CT (ΔCT) values were calculated as the normalized CT values of each target gene in relation to the CT of endogenous controls GUS-β. 505 Then, ΔΔCT values were obtained from the ΔCT of each sample minus the mean ΔCT of the population of control samples. ). Outliers were detected using the GraphPad software QuickCalcs (P < 0.05). All data were expressed as mean values ± SEM. Differences between controls and 525 CJD MM1 or CJD VV2 were considered statistically significant at * P < 0.05, ** P < 0.01, *** P < 0.001; and set at $ P < 0.05 and $$ P < 0.01when comparing CJD MM1 and CJD VV2.
Statistical analysis
Immunohistochemistry
530 De-waxed sections, 4 microns thick, were processed for immunohistochemistry (control n = 8; CJD MM1 n = 6; CJD VV2 n = 2). The sections were boiled in citrate buffer (20min) to retrieve tau antigenicity. Endogenous peroxidases were blocked by incubation in 10% methanol-1% 535 H 2 O 2 solution (15min) followed by 3% normal horse serum solution. Then the sections were incubated at 4ºC overnight with one of the primary antibodies against glial fibrillary acidic protein (GFAP) (rabbit polyclonal, used at 1:500, Dako, Glostrup, DK), Olig-2 (rabbit polyclonal, 540 used at 1:500, Abcam, Cambridge, UK), aquaporine 4 (AQP4) (monoclonal, used at 1:400, Sigma, St Louis, Missouri, USA), solute carrier family 1 member 2 (GLT1) (guinea pig used at 1:100, Merck-Millipore, Billerica, MA, USA), mitochondrial pyruvate carrier 1 545 (MPC1) MPC1) (polyclonal, used at 1:100, Cell Signaling Technology, Danvers, MA, USA), mitochondrial uncoupled protein 5 (UCP5) (polyclonal, used at 1:10, Novus Biological, Littleton, CO, USA), solute carrier family 2 member 1 (GLUT1) (polyclonal, used at 1:100, 550 Abcam, Cambridge, CB, UK) and solute carrier family 16 member 1 (MCT1) (monoclonal, used at 1:50, Sigma, St Louis, Missouri, USA). Following incubation with Following incubation with the primary antibody, the sections were incubated with EnVision + system peroxidase 555 (Dako, DK) for 30min at room temperature. The peroxidase reaction was visualized with diaminobenzidine and H 2 O 2 . Control of the immunostaining included omission of the primary antibody; no signal was obtained following incubation with only the secondary antibody. Peptides for 560 pre-absorption studies were not available.
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